Aspire Biopharma Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Shareholders’ Deficit
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Deficit | |
| Balance - January 1, 2025 | 690,044 | $69 | $1,237,076 | $(2,777,233) | $(1,540,088) |
| Conversion of warrants | 143,393 | 14 | (14) | - | - |
| Issuance of shares in Reverse Recapitalization | 209,101 | 20 | (4,602,596) | - | (4,602,576) |
| Issuance of shares under working capital loans and non redemption agreements | 138,424 | 14 | (14) | - | - |
| Issuance of commitment fee shares under ELOC agreement | 75,326 | 8 | 274,992 | - | 275,000 |
| Shares issued pursuant to settlement agreement | 15,625 | 2 | 317,248 | - | 317,250 |
| Stock-based compensation | 41,563 | 4 | 14,131,246 | - | 14,131,250 |
| Conversion of convertible notes | 2,219,932 | 222 | 9,523,461 | - | 9,523,683 |
| Net loss | - | - | - | (24,480,848) | (24,480,848) |
| Balance – December 31, 2025 | 3,533,408 | $353 | $20,881,399 | $(27,258,081) | $(6,376,329) |
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Deficit | |
| Balance - January 1, 2024 | 11,000,000 | $22,000 | $957,500 | $(1,467,361) | $(487,861) |
| Retroactive application of Reverse Recapitalization | (10,310,461) | (21,931) | 21,931 | - | - |
| Balance - January 1, 2024, after retroactive application of Reverse Recapitalization | 689,539 | 69 | 979,431 | (1,467,361) | (487,861) |
| Issuance of common stock | 505 | - | 257,645 | - | 257,645 |
| Net loss | - | - | - | (1,309,872) | (1,309,872) |
| Balance - December 31, 2024 | 690,044 | $69 | $1,237,076 | $(2,777,233) | $(1,540,088) |
The Company’s common stock shares issued and outstanding, common stock and additional paid-in capital as of December 31, 2025 and 2024 have been retroactively restated for the reverse stock split as described in Note 3 of the accompanying notes, which are an integral part of these consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.